More particularly, the Court affirmed the FCA’s conclusion that Janssen infringed competition law by, on the one hand, disparaging competing fentanyl specialties towards health professionals, emphasizing the risks associated with a switch from Durogesic© to a generic version and, on the other hand, intervening in the French Health Authority’s (“ANSM”, formerly AFSSAPS) process to oppose the listing of Ratiopharm’s specialty as a generic drug of Durogesic©. The Court, however, granted Janssen a small decrease in fine (from €25 million to €21 million ) considering that its actions did not aim at challenging Ratiopharm’s marketing authorization but only the listing in France of its fentanyl specialty as a generic version of Durogesic©. While the Court followed in the footsteps of precedents with
The Paris Court of Appeal upholds the decision of the Competition Authority to fine a pharma company for abuse of dominance (Jansson-Cilag / Johnson & Johnson)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.